

ClinicalTrials.gov: cell therapy | Last update posted in the last 7 days

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
1	NCT04115345	A Study of a Renal Autologous Cell Therapy (REACT®) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Study Documents:	Title Acronym: Other Ids: REGEN-004	Recruiting	<ul style="list-style-type: none">Chronic Kidney DiseaseCongenital Anomalies of Kidney and Urinary Tract	Biological: Renal Autologous Cell Therapy (REACT®) Autologous selected renal cells (SRC)	<div>Study Type: Interventional</div> <div>Phase: Phase 1</div> <div>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: Open-label Masking: None (Open Label) Primary Purpose: Treatment</div> <div>Primary Outcome Measures: Assess change in eGFR and observe incidence of renal-specific procedure and/or product related adverse events (AEs) through 24 months following two Renal Autologous Cell Therapy (REACT) injections [Safety]. [Time Frame: 12 months following last REACT injection] The primary objective is to assess the safety and optimal delivery of Renal Autologous Cell Therapy (REACT) injected at one site in a recipient kidney as measured by procedure- and/or product related adverse events (AEs) through 12 months post-treatment.</div> <div>Secondary Outcome Measures: Number of subjects with renal-specific adverse events over a 24-month period following injection of Renal Autologous Cell Therapy (REACT). [Time Frame: 24 months following last REACT injection] The number of subjects with renal-specific adverse events over a 24-month period following injection of Renal Autologous Cell Therapy (REACT) will be observed utilizing renal-specific laboratory assessments.The secondary objective will compare the results of laboratory tests from baseline through 12 months following REACT injection, followed by an additional observational period of 18 months for a total of 24 months of observation. Each subject's baseline rate of CKD disease progression serves as his/her own "control" to monitor for changes in renal insufficiency over time.</div>	<div>Actual Enrollment:</div> <div>Estimated Enrollment: 15</div> <div>Original Estimated Enrollment: <i>Same as current</i></div> <div>Age: 18 Years to 65 Years (Adult, Older Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: <i>Same as current</i></div> <div>Collaborators: CTI Clinical Trial and Consulting Services</div>	<div>Study Start: August 13, 2019</div> <div>Primary Completion: March 31, 2023 (Final data collection date for primary outcome measure)</div> <div>Study Completion: May 30, 2023</div> <div>First Posted: October 4, 2019</div> <div>Results First Posted:</div> <div>Last Update Posted: September 16, 2022</div>
2	NCT05237986	Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy Study Documents:	Title Acronym: Other Ids: 10000631 000631-C	Not yet recruiting	<ul style="list-style-type: none">LymphomaLeukemia	Not Provided	<div>Study Type: Observational</div> <div>Phase:</div> <div>Study Design: Observational Model: Cohort Time Perspective: Prospective</div> <div>Primary Outcome Measures: <i>Same as current</i></div> <div>Secondary Outcome Measures: <i>Same as current</i></div>	<div>Actual Enrollment:</div> <div>Estimated Enrollment: 60</div> <div>Original Estimated Enrollment: <i>Same as current</i></div> <div>Age: 5 Years and older (Child, Adult, Older Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: <i>Same as current</i></div> <div>Collaborators: Not Provided</div>	<div>Study Start: September 21, 2022</div> <div>Primary Completion: April 30, 2024 (Final data collection date for primary outcome measure)</div> <div>Study Completion: April 30, 2025</div> <div>First Posted: February 14, 2022</div> <div>Results First Posted:</div> <div>Last Update Posted: September 16, 2022</div>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
3	NCT03240328	The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function Study Documents:	Title Acronym: Other Ids: 20170407V3	Recruiting	HIV/AIDS	Biological: CAR-T cells HIV-1 specific chimeric antigen receptor cells	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: No control. Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: Incidence of Treatment-Emergent Adverse Events of CAR-T cell therapy [Time Frame: 6 Months] The adverse events of VC-CAR-T cell therapy on HIV-infected patients during the clinical trial Secondary Outcome Measures: The HIV reservoir [Time Frame: 6 Months] To assay the HIV loads in the peripheral blood Mono-nuclear cells and plasma	Actual Enrollment: Estimated Enrollment: 40 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years to 60 Years (Adult) Sex: All	Study Sponsors: Same as current Collaborators: Sun Yat-sen University	Study Start: October 4, 2017 Primary Completion: December 31, 2023 (Final data collection date for primary outcome measure) Study Completion: December 31, 2030 First Posted: August 7, 2017 Results First Posted: Last Update Posted: September 14, 2022
4	NCT05541549	A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML Study Documents:	Title Acronym: Other Ids: 20210001	Not yet recruiting	Progressive Multifocal Leukoencephalo pathy	Biological: CE-VST01-JC CE-VST01-JC at a dose of 1×10^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions	Study Type: Interventional Phase: Phase 2 Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: randomized, double- blinded, Phase 2 trial in patients with PML due to JCPyV. Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Primary Outcome Measures: To evaluate the effect of CE-VST01-JC on time to disease progression, as measured by mRS (modified Rankin Score) [Time Frame: 1 year] Time to progression as measured by mRS. A progression event is defined as an increase of 2 points on mRS attributable to disease progression* that is durable (not reversed over two consecutive measurements, at least 14 days apart), or an increase to mRS of 5 or 6 (severe disability or death, respectively). Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 60 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: Not Provided	Study Start: February 2023 Primary Completion: March 2024 (Final data collection date for primary outcome measure) Study Completion: April 2025 First Posted: September 15, 2022 Results First Posted: Last Update Posted: September 16, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
5	NCT03696030	HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Study Documents:	Title Acronym: Other Ids: 17237 NCI-2018-01270 (Registry Identifier: CTRP (Clinical Trial Reporting Program)) 17237 (Other Identifier: City of Hope Medical Center)	Recruiting	<ul style="list-style-type: none">• Malignant Neoplasm• Metastatic Malignant Neoplasm in the Brain• Metastatic Malignant Neoplasm in the Leptomeninges• Breast Cancer• HER2-positive Breast Cancer	Biological: Chimeric Antigen Receptor T-Cell Therapy Given HER2-CAR T cells via intraventricular administration Other Names: <ul style="list-style-type: none">• CAR T Infusion• CAR T Therapy• CAR T-cell therapy• Chimeric Antigen Receptor T-cell Infusion	<div>Study Type: Interventional</div> <div>Phase: Phase 1</div> <div>Study Design: Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</div> <div>Primary Outcome Measures:<ul style="list-style-type: none">• Incidence of dose limiting toxicities (DLTs) [Time Frame: 21 days post T cell infusion] Rate and associated 90% Clopper and Pearson binomial confidence limits (90% CI) will be estimated for participants experiencing DLTs at the recommended phase 2 dose schedule.• Number of participants with treatment related adverse events as assessed by CTCAE v5.0. [Time Frame: Up to 15 years] Tables will be created to summarize all toxicities and side effects by dose, time post treatment, organ, severity and arm.</div> <div>Secondary Outcome Measures:<ul style="list-style-type: none">• HER2-CAR T cells in cerebrospinal fluid (CSF) and peripheral blood [Time Frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6,and 12 months, not progressed: baseline, 1, 3,6,8,10 and 12 months)] Statistical and graphical methods will be used to describe the data.• Endogenous B cells in cerebrospinal fluid (CSF) and peripheral blood [Time Frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6,and 12 months, not progressed: baseline, 1, 3,6,8,10 and 12 months)] Statistical and graphical methods will be used to describe the data.• T cells in cerebrospinal fluid (CSF) and peripheral blood [Time Frame: progressed: baseline, 1, 3, 6, and 12 months, not progressed: baseline, 1, 3, 6, 8,10 and 12 months)] Statistical and graphical methods will be used to describe the data.• Myeloid cells in cerebrospinal fluid (CSF) and peripheral blood [Time Frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6,and 12 months, not progressed: baseline, 1, 3,6,8,10 and 12 months)] Statistical and graphical methods will be used to describe the data.• Host immune subsets (e.g. T cell inhibitory/exhaustion markers, activation markers, and effector memory T cells) in cerebrospinal fluid (CSF) and peripheral blood. [Time Frame: Measured over time from baseline through 1 year, the number of measurements is determined by whether or not the participant has progressed (progressed: baseline, 1, 3, 6,and 12 months, not progressed: baseline, 1, 3,6,8,10 and 12 months)] Statistical and graphical methods will be used to describe the data.</div>	<div>Actual Enrollment:</div> <div>Estimated Enrollment: 39</div> <div>Original Estimated Enrollment: 21</div> <div>Age: 18 Years to 75 Years (Adult, Older Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: Same as current</div> <div>Collaborators:<ul style="list-style-type: none">• National Cancer Institute (NCI)• California Institute for Regenerative Medicine (CIRM)</div>	<div>Study Start: August 31, 2018</div> <div>Primary Completion: August 31, 2023 (Final data collection date for primary outcome measure)</div> <div>Study Completion: August 31, 2023</div> <div>First Posted: October 4, 2018</div> <div>Results First Posted:</div> <div>Last Update Posted: September 16, 2022</div>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
6	NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Study Documents:	Title Acronym: Other Ids: 18-001989 NCI-2019-03190 (Registry Identifier: CTRP (Clinical Trial Reporting Program)) 18-001989 (Other Identifier: UCLA / Jonsson Comprehensive Cancer Center)	Recruiting	<ul style="list-style-type: none">CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma	<ul style="list-style-type: none">Biological: Chimeric Antigen Receptor T-Cell Therapy Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV Other Names:<ul style="list-style-type: none">CAR T InfusionCAR T TherapyCAR T-cell therapyChimeric Antigen Receptor T-cell InfusionDrug: Cyclophosphamide Given IV Other Names:<ul style="list-style-type: none">(-)-Cyclophosphamide2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrateCarloxanCiclofosfamidaCiclofosfamideCicloxalClafenClapheneCP (cyclophosphamide) monohydrateCTX (cytoxan)CYCLO-cellCycloblastinCycloblastineCyclophosphamCyclophosphamid monohydrateCyclophosphamidumCyclophosphanCyclophosphaneCyclophosphanumCyclostinCyclostineCytophosphanCytophosphaneCytoxanFosfaseronGenoxalGenuxalLedoxinaMitoxanNeosarRevimmuneSyklofosfamidWR- 138719Drug: Fludarabine Phosphate Given IV Other Names:<ul style="list-style-type: none">2-F-ara-AMP fludarabine: 2-Fluoroadenine 9-beta-D-Arabinofuranoside 5'-Monophosphate9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-BeneflurFludaraSH T 586Biological: Tocilizumab Given IV Other Names:<ul style="list-style-type: none">ActemraImmunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, DimerMRA (myeloma receptor antibody)R-1569RoActemra	<div>Study Type: Interventional</div> <div>Phase: Phase 1</div> <div>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</div> <div>Primary Outcome Measures: <i>Same as current</i></div> <div>Secondary Outcome Measures:<ul style="list-style-type: none">Clinical response [Time Frame: Up to 15 years] Descriptive statistics including simple summary measures and plots appropriate for longitudinal data will be used.Duration of remission [Time Frame: Time from complete remission (CR)/partial remission (PR) measurement criteria are first met until the first date that recurrent or progressive disease is objectively documented, or until death, assessed up to 15 years] Descriptive statistics including simple summary measures and plots appropriate for longitudinal data will be used. Will also be summarized descriptively (mean, standard deviation, median, first and third quartiles, minimum, maximum). Figures showing the Kaplan-Meier estimates will also be presented.Objective response rate (ORR) [Time Frame: Up to 15 years] Descriptive statistics including simple summary measures and plots appropriate for longitudinal data will be used. ORR and the individual rate for CR and PR will be summarized with the frequency count and the percentage of subjects in each category, along with a 2-sided 95% exact confidence interval.Progression-free survival [Time Frame: From time of study entry to documentation of objective disease progression or death due to any cause assessed up to 15 years] Descriptive statistics including simple summary measures and plots appropriate for longitudinal data will be used. Will also be summarized descriptively (mean, standard deviation, median, first and third quartiles, minimum, maximum). Figures showing the Kaplan-Meier estimates will also be presented.Overall survival [Time Frame: From date of enrollment until death, assessed up to 15 years] Descriptive statistics including simple summary measures and plots appropriate for longitudinal data will be used. Will be summarized with figures using the Kaplan-Meier method. The Kaplan-Meier estimates for the 1-year OS rates and the 2-sided 95% confidence interval of the rates using the Greenwood's formula will be reported. Will also be summarized descriptively (mean, standard deviation, median, first and third quartiles, minimum, maximum).Chimeric antigen receptor (CAR) T-cell (T) 19/20 bispecific transgenic T-cell persistence [Time Frame: Up to 5 years post-infusion] Descriptive statistics of T-cell counts over time, including simple summary measures and plots appropriate for longitudinal data will be used.Frequency of T cell phenotypic markers on CART19/20 cells using flow cytometry [Time Frame: Up to 5 years post-infusion] The frequency of CART19/20 cell properties will be assessed using flow cytometry to indicate the % and/or total number of CART19/20 cells expressing critical</div>	<div>Actual Enrollment:</div> <div>Estimated Enrollment: 24</div> <div>Original Estimated Enrollment: <i>Same as current</i></div> <div>Age: 18 Years to 70 Years (Adult, Older Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: <i>Same as current</i></div> <div>Collaborators: Parker Institute for Cancer Immunotherapy</div>	<div>Study Start: October 4, 2019</div> <div>Primary Completion: August 1, 2023 (Final data collection date for primary outcome measure)</div> <div>Study Completion: August 1, 2024</div> <div>First Posted: July 5, 2019</div> <div>Results First Posted:</div> <div>Last Update Posted: September 13, 2022</div>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
7	NCT05050006	ITIL-168 in Advanced Melanoma Study Documents:	Title Acronym: Other Ids: ITIL-168-101 2020-003862-37 (EudraCT Number)	Recruiting	Advanced Cutaneous Melanoma	Biological: ITIL-168 ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.	Study Type: Interventional Phase: Phase 2 Study Design: Allocation: Non-Randomized Intervention Model: Parallel Assignment Intervention Model Description: All enrolled participants are assigned to be treated with a single dose of ITIL-168 Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 130 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: <i>Same as current</i> Collaborators: Not Provided	Study Start: October 7, 2021 Primary Completion: March 2024 (Final data collection date for primary outcome measure) Study Completion: August 2028 First Posted: September 20, 2021 Results First Posted: Last Update Posted: September 16, 2022
8	NCT04684459	Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis Study Documents:	Title Acronym: Other Ids: MCART-002	Recruiting	<ul style="list-style-type: none">Peritoneal Carcinoma MetastaticPleural Effusion, Malignant	Biological: Dual-targeting HER2 and PD-L1 CAR-T cells serosal cavity infusion	Study Type: Interventional Phase: Early Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 18 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	Study Sponsors: <i>Same as current</i> Collaborators: Not Provided	Study Start: March 12, 2021 Primary Completion: January 1, 2023 (Final data collection date for primary outcome measure) Study Completion: January 1, 2024 First Posted: December 24, 2020 Results First Posted: Last Update Posted: September 13, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
9	NCT05540964	An Antiretroviral Treatment Interruption(ATI) Study to Evaluate the Impact of AGT103-T to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy Study Documents:	Title Acronym: Other Ids: AGT-HC-169	Enrolling by invitation	HIV	Other: Antiretroviral Therapy Interruption(ATI) Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: All study participant that consent to the study will be withdrawn from their Antiretroviral Therapy(ART) and monitored closely by clinic visit and laboratory testing of blood sample collected during each visit. Masking: None (Open Label) Primary Purpose: Diagnostic Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 7 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: <i>Same as current</i> Collaborators: Not Provided	Study Start: July 19, 2022 Primary Completion: July 19, 2025 (Final data collection date for primary outcome measure) Study Completion: July 19, 2025 First Posted: September 15, 2022 Results First Posted: Last Update Posted: September 15, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
10	NCT04310592	Natural Killer Cell (CYNK-001) Infusions in Adults With AML Study Documents:	Title Acronym: Other Ids: CYNK-001-AML-001	Recruiting	<ul style="list-style-type: none">LeukemiaLeukemia, MyeloidLeukemia, Myeloid, AcuteNeoplasms by Histologic TypeNeoplasmsImmunosuppressive AgentsImmunologic FactorsPhysiological Effects of DrugsAlkylating AgentsAntimetabolites, AntineoplasticAntiviral AgentsAnalgesics, Non-narcoticAnti-infective AgentsAnalgesicsPeripheral Nervous System AgentsHematologic DiseasesHematologic NeoplasmsLeukemia in RemissionRelapsed Adult AMLRefractory AML	Biological: CYNK-001 CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: Non-Randomized Intervention Model: Parallel Assignment Intervention Model Description: Experimental: Minimal Residual Disease (MRD) positive AML patients; Cyclophosphamide + Fludarabine + CYNK-001. On Days 0, 7, and 14, (and 21 in certain arms) CYNK-001 at 3 varying dose levels. Experimental: Relapsed/Refractory AML patients; Cyclophosphamide + Fludarabine + CYNK-001. On Days 0, 7, and 14, (and 21 at certain dose levels) CYNK-001 at 3 varying dose levels. Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <ul style="list-style-type: none">Number of Participants who experience a Dose-limiting Toxicity (DLT) [Time Frame: Day +28] The number of participants who experience a DLT will be measured.Determine the Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD) of CYNK-001 [Time Frame: up to 28 days] The maximum dose safely administered for the treatment of patients with AML.Frequency and Severity of Adverse Events (AEs) [Time Frame: up to 12 months] Frequency and severity of Adverse Events will be evaluated. Secondary Outcome Measures: <ul style="list-style-type: none">Number of Participants who experience Minimal Residual Disease (MRD) Response [Time Frame: up to 12 months] The number of participants who convert from MRD positive to MRD negative.Time to MRD Response [Time Frame: up to 12 months] The time it takes to convert from MRD positive to MRD negative.Duration of MRD Response [Time Frame: up to 12 months] The measure of how long participants remain MRD negative.Progression-free Survival (PFS) [Time Frame: up to 12 months] Date of first CYNK-001 infusion to date of disease progression.Time to Progression (TTP) [Time Frame: up to 12 months] Date of first CYNK-001 infusion to date of disease progression.Duration of Morphologic Complete Remission (CR) [Time Frame: up to 12 months] Duration from first Morphologic CR observation to time of disease progression.Overall Survival (OS) [Time Frame: up to 12 months] Date of first CYNK-001 infusion to date of death.	Actual Enrollment: Estimated Enrollment: 94 Original Estimated Enrollment: 22 Age: 18 Years to 80 Years (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: Not Provided	Study Start: March 12, 2020 Primary Completion: June 3, 2024 (Final data collection date for primary outcome measure) Study Completion: December 3, 2024 First Posted: March 17, 2020 Results First Posted: Last Update Posted: September 14, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
11	NCT00001405	Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes Study Documents:	Title Acronym: Other Ids: 940073 94-I-0073	Recruiting	<ul style="list-style-type: none">• Granuloma• Granulomatous Disease, Chronic• Leukocyte Disease• Genetic Disease, X-Linked• Genetic Disease, Inborn	Not Provided	Study Type: Observational Phase: Study Design: Observational Model: Cohort Time Perspective: Other Primary Outcome Measures: Not Provided Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 850 Original Estimated Enrollment: Age: 18 Years to 70 Years (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: Not Provided	Study Start: February 27, 1994 Primary Completion: Not Provided Study Completion: Not Provided First Posted: November 4, 1999 Results First Posted: Last Update Posted: September 15, 2022
12	NCT05539768	Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor Study Documents:	Title Acronym: Other Ids: HS-IT101-ST001	Not yet recruiting	Advanced Solid Tumor	Biological: HS-IT101 Adoptive transfer of 1x10^9-6x10^10 autologous TIL to patients i.v. in 30-60 minutes.	Study Type: Interventional Phase: Early Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 8 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: Qingdao Sino-Cell Biomedicine Co.,Ltd.	Study Start: October 8, 2022 Primary Completion: December 31, 2023 (Final data collection date for primary outcome measure) Study Completion: March 31, 2027 First Posted: September 14, 2022 Results First Posted: Last Update Posted: September 14, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
13	NCT05544526	CAR T Cells to Target GD2 for DMG Study Documents:	Title Acronym: Other Ids: UCL/150853	Not yet recruiting	Diffuse Midline Glioma, H3 K27M-Mutant	Biological: GD2 CAR T cells Infusion with: GD2 CAR T-cells	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 12 Original Estimated Enrollment: <i>Same as current</i> Age: up to 16 Years (Child) Sex: All	Study Sponsors: <i>Same as current</i> Collaborators: Not Provided	Study Start: December 2022 Primary Completion: December 2025 (Final data collection date for primary outcome measure) Study Completion: December 2039 First Posted: September 16, 2022 Results First Posted: Last Update Posted: September 16, 2022
14	NCT04088864	CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Study Documents:	Title Acronym: Other Ids: IRB-50878 CCT6003 (Other Identifier: OnCore) IRB-50878 (Other Identifier: Stanford IRB) NCI-2019-07285 (Other Identifier: NCI Trial Identifier)	Suspended	<ul style="list-style-type: none">B Cell LymphomaAcute Lymphoblastic Leukemia, PediatricLymphoma	<ul style="list-style-type: none">Drug: Fludarabine Fludarabine is a purine antagonist antimetaboliteDrug: Cyclophosphamide Cyclophosphamide is a nitrogen mustard derivative alkylating agentDrug: Autologous CD22 CAR T Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 52 Original Estimated Enrollment: <i>Same as current</i> Age: 1 Year to 30 Years (Child, Adult) Sex: All	Study Sponsors: <i>Same as current</i> Collaborators: Not Provided	Study Start: January 10, 2020 Primary Completion: August 2025 (Final data collection date for primary outcome measure) Study Completion: August 2035 First Posted: September 13, 2019 Results First Posted: Last Update Posted: September 13, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
15	NCT00012545	Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease Study Documents:	Title Acronym: Other Ids: 010122 01-H-0122	Recruiting	<ul style="list-style-type: none">Sickle Cell DiseaseSickle Cell Trait	Not Provided	Study Type: Observational Phase: Study Design: Observational Model: Case-Only Time Perspective: Cross-Sectional Primary Outcome Measures: Not Provided Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 352 Original Estimated Enrollment: Age: 18 Years to 45 Years (Adult) Sex: All	Study Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Collaborators: Not Provided	Study Start: November 1, 2001 Primary Completion: Not Provided Study Completion: Not Provided First Posted: March 12, 2001 Results First Posted: Last Update Posted: September 13, 2022
16	NCT05472558	Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL Study Documents:	Title Acronym: Other Ids: 2022-0496	Recruiting	B-cell Non Hodgkin Lymphoma	Biological: anti-CD19 CAR-NK lentiviral vector-transduced cord blood-derived NK cells to express anti-CD19 CAR Other Name: CB CAR-NK019	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 48 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years to 75 Years (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: Not Provided	Study Start: September 10, 2022 Primary Completion: September 10, 2023 (Final data collection date for primary outcome measure) Study Completion: September 10, 2025 First Posted: July 25, 2022 Results First Posted: Last Update Posted: September 13, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
17	NCT04102436	Non-Viral TCR Gene Therapy Study Documents:	Title Acronym: Other Ids: 190143 19-C-0143	Recruiting	<ul style="list-style-type: none">Endocrine/NeuroendocrineNon-Small Cell Lung CancerBreast CancerGastrointestinal/Genitourinary CancersOvarian Cancer	<ul style="list-style-type: none">Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.Drug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.Drug: Aldesleukin Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).Biological: Sleeping Beauty Transposed PBL Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).	<div>Study Type: Interventional</div> <div>Phase: Phase 2</div> <div>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</div> <div>Primary Outcome Measures: <i>Same as current</i></div> <div>Secondary Outcome Measures:<ul style="list-style-type: none">Phenotypic and functional characteristics of PBL [Time Frame: 2-4 years post cell infusion] Patient PBL will be obtained from whole blood and then evaluated for function and phenotypeSafety and tolerance [Time Frame: 6 weeks (+/- 2 weeks) following administration of the cell product] Using standard CTCAE 5.0</div>	<div>Actual Enrollment:</div> <div>Estimated Enrollment: 210</div> <div>Original Estimated Enrollment: <i>Same as current</i></div> <div>Age: 18 Years to 70 Years (Adult, Older Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: <i>Same as current</i></div> <div>Collaborators: Not Provided</div>	<div>Study Start: September 21, 2022</div> <div>Primary Completion: December 31, 2028 (Final data collection date for primary outcome measure)</div> <div>Study Completion: December 31, 2029</div> <div>First Posted: September 25, 2019</div> <div>Results First Posted:</div> <div>Last Update Posted: September 16, 2022</div>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
18	NCT03654040	Liver Transplantation With Tregs at UCSF Study Documents:	Title Acronym: Other Ids: DAIT ITN074ST UM1AI109565 (U.S. NIH Grant/Contract) NIAID CRMS ID#: 38481 (Other Identifier: DAIT NIAID)	Recruiting	Liver Transplant	<ul style="list-style-type: none">Biological: arTreg Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10^6 total cells. Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes. Other Names:<ul style="list-style-type: none">donor alloantigen-reactive regulatory T cellsCD4+CD25+CD127[lo] Treg cellsProcedure: leukapheresis Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen. Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion. Other Name: apheresisDrug: cyclophosphamide 40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care. Other Names:<ul style="list-style-type: none">Cytoxan®CTXDrug: mesna Mesna is administered:<ul style="list-style-type: none">Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, andIn conjunction with the cyclophosphamide, per institutional practice with CTX. Other Name: Mesnex®Drug: everolimus EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is 50 U/L, GGT LFT is the upper limit of normal or 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time. Other Names:<ul style="list-style-type: none">EVRAfinitor®Zortress®	<p>Study Type: Interventional</p> <hr/> <p>Phase: Phase 1 Phase 2</p> <hr/> <p>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</p> <hr/> <p>Primary Outcome Measures:</p> <ul style="list-style-type: none">Number of Adverse Events (AEs) Attributed to the Investigational Product, arTreg [Time Frame: From arTreg infusion through completion of study participation (Up to 4.5 years)] The number of AEs attributed to the investigational product, arTreg. AEs will be attributed to arTreg when the AE is reported with possible or related attribution to arTreg.Severity of Adverse Events (AEs) Attributed to the Investigational Product, arTreg [Time Frame: From arTreg infusion through completion of study participation (Up to 4.5 years)] Assessment of the intensity of AEs attributed to the investigational product, arTreg. AEs will be attributed to arTreg when the AE is reported with possible or related attribution to arTreg. Grading according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 5.0].Number of Adverse Events (AEs) Attributed to the Investigational Product's Supportive Regimen (Leukapheresis, Cyclophosphamide and Mesna) [Time Frame: From 3 days prior to arTreg infusion through completion of study participation (Up to 4.5 years)] The number of AEs attributed to the investigational product's supportive regimen (leukapheresis, cyclophosphamide, and mesna). AEs will be attributed to the supportive regimen when the AE is reported with possible or related attribution to leukapheresis, cyclophosphamide, or mesna.Severity of Adverse Events (AEs) Attributed to the Investigational Product's Supportive Regimen (Leukapheresis, Cyclophosphamide and Mesna) [Time Frame: From 3 days prior to arTreg infusion through completion of study participation (Up to 4.5 years)] Assessment of the intensity of AEs attributed to the investigational product's supportive regimen (e.g., leukapheresis, cyclophosphamide, and mesna). AEs will be attributed to the supportive regimen when the AE is reported with possible or related attribution to leukapheresis, cyclophosphamide, or mesna. Assessment of the intensity of AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events [NCI-CTCAE version 5.0].Number of Operationally Tolerant Participants [Time Frame: 52 weeks (±4 weeks) after the last dose of immunosuppression] Operational tolerance is defined as:<ul style="list-style-type: none">Discontinuation of immunosuppression for 52 weeks,Alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) 50 U/L, andA liver biopsy at 52 weeks (±4 weeks) after the last dose of immunosuppression that meets the criteria noted per protocol.<ul style="list-style-type: none">Liver histology will be assessed by central pathology. <hr/> <p>Secondary Outcome Measures:</p>	<p>Actual Enrollment:</p> <hr/> <p>Estimated Enrollment: 9</p> <hr/> <p>Original Estimated Enrollment: <i>Same as current</i></p> <hr/> <p>Age: 18 Years to 70 Years (Adult, Older Adult)</p> <hr/> <p>Sex: All</p>	<p>Study Sponsors: Same as current</p> <hr/> <p>Collaborators:</p> <ul style="list-style-type: none">Immune Tolerance Network (ITN)PPDRho Federal Systems Division, Inc.	<p>Study Start: April 22, 2021</p> <hr/> <p>Primary Completion: April 2025 (Final data collection date for primary outcome measure)</p> <hr/> <p>Study Completion: March 2028</p> <hr/> <p>First Posted: August 31, 2018</p> <hr/> <p>Results First Posted:</p> <hr/> <p>Last Update Posted: September 14, 2022</p>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
19	NCT05239143	P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors Study Documents:	Title Acronym: Other Ids: P-MUC1C-ALLO1-001	Recruiting	<ul style="list-style-type: none">Breast CancerOvarian CancerNon Small Cell Lung CancerColorectal CancerPancreatic CancerRenal Cell CarcinomaNasopharyngeal CancerHead and Neck Squamous Cell CarcinomaGastric Cancer	<ul style="list-style-type: none">Biological: P-MUC1C-ALLO1 CAR-T cells P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.Drug: Rimiducid Rimiducid (safety switch activator) may be administered as indicated.	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: Non-Randomized Intervention Model: Sequential Assignment Intervention Model Description: Open label, 3 + 3 design of dose-escalating cohorts with open label, dose expansion at recommended phase 2 dose (RP2D) Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: Not Provided	Actual Enrollment: Estimated Enrollment: 100 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: Not Provided	Study Start: February 15, 2022 Primary Completion: April 2026 (Final data collection date for primary outcome measure) Study Completion: April 2039 First Posted: February 14, 2022 Results First Posted: Last Update Posted: September 13, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
20	NCT04318964	TAEST16001 in the Treatment of Soft Tissue Sarcoma Study Documents:	Title Acronym: Other Ids: SunYat-senU-TAEST16001	Recruiting	Soft Tissue Sarcoma	<p>Biological: TAEST16001 cells</p> <p>The patients in the dose increasing part and the expanding part received the intravenous reinfusion of TAEST16001 cells on the 5th day (i.e. the interval was 4 days) after the lymphocyte elimination chemotherapy: If the dose level of reinfusion was 1 and 2, the planned total amount of TAEST16001cells (calculated by TCR-T positive cells) was given a single reinfusion on the 1st day of the study. If the dose level of reinfusion was 3 and 4,then the total amount of TAEST16001cells (calculated by TCR-T positive cells) was planned to be reinjected in 60% and 40% proportion on the first and second day of the study.</p> <p>After the first reinfusion of TAEST16001 cells, the patients will be given a small dose of IL-2 subcutaneously (study day 1 to day 14), 500000 U / time. The first injection will be carried out within 30 minutes after the cell reinfusion, twice a day (interval 10-12 hours), for 14 days.</p>	<p>Study Type: Interventional</p> <hr/> <p>Phase: Phase 1</p> <hr/> <p>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</p> <hr/> <p>Primary Outcome Measures: <i>Same as current</i></p> <hr/> <p>Secondary Outcome Measures:</p> <ul style="list-style-type: none">Peripheral blood TAEST16001 cell peak (C Max) [Time Frame: Time Frame: From cell infusion up to 28 days] The maximum concentration of TAEST16001 cells observed in peripheral blood, and TAEST16001 cells were detected by flow cytometry and TCR-T DNA was detected by qPCRPeripheral blood TAEST16001 cell peak time (T Max) [Time Frame: Time Frame: From cell infusion up to 28 days] The time required to observe maximum concentration of TAEST16001 cells in peripheral blood, TAEST16001 cells were detected by flow cytometry and TCR-T DNA was detected by qPCRPeripheral blood TAEST16001 cell AUC 0-28 [Time Frame: Time Frame: From cell infusion up to 28 days] Area under the Concentration-time Curve from Zero up to a Definite Time Day 28T cell subsets [Time Frame: Time Frame: From cell infusion up to 28 days] 5mL venous blood was collected and sent to the center for flow cytometryPeripheral blood antigen-specific CTL [Time Frame: Time Frame: From cell infusion up to 28 days] 5mL venous blood was collected and sent to the center for flow cytometry of cytotoxic T CellEffector cell activity [Time Frame: Time Frame: From cell infusion up to 28 days] 5mL venous blood was collected and sent to the center for flow cytometry of cytokines secreted by effector cells	<p>Actual Enrollment:</p> <hr/> <p>Estimated Enrollment: 12</p> <hr/> <p>Original Estimated Enrollment: <i>Same as current</i></p> <hr/> <p>Age: 18 Years to 70 Years (Adult, Older Adult)</p> <hr/> <p>Sex: All</p>	<p>Study Sponsors: Same as current</p> <hr/> <p>Collaborators: Guangdong Xiangxue Precision Medical Technology Co., Ltd.</p>	<p>Study Start: March 19, 2020</p> <hr/> <p>Primary Completion: November 1, 2022 (Final data collection date for primary outcome measure)</p> <hr/> <p>Study Completion: March 1, 2023</p> <hr/> <p>First Posted: March 24, 2020</p> <hr/> <p>Results First Posted:</p> <hr/> <p>Last Update Posted: September 15, 2022</p>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
21	NCT05539183	Collection of Pleural Effusion Fluid Study Documents:	Title Acronym: Other Ids: 22151PLEUREF	Not yet recruiting	<ul style="list-style-type: none">Solid TumorPleural EffusionMetastasis	Procedure: Blood withdrawal Blood withdrawal	Study Type: Interventional Phase: Not Applicable Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Basic Science Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 50 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: Vrije Universiteit Brussel	Study Start: October 1, 2022 Primary Completion: December 31, 2024 (Final data collection date for primary outcome measure) Study Completion: December 31, 2025 First Posted: September 14, 2022 Results First Posted: Last Update Posted: September 14, 2022
22	NCT05370430	BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory MCL Study Documents:	Title Acronym: Other Ids: PMB-102 PMB-BAFFR-102 (Other Identifier: PeproMeneBio)	Recruiting	Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Biological: BAFFR-CAR T cells First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r MCL	Study Type: Interventional Phase: Phase 1 Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Primary Outcome Measures: <i>Same as current</i> Secondary Outcome Measures: <i>Same as current</i>	Actual Enrollment: Estimated Enrollment: 18 Original Estimated Enrollment: <i>Same as current</i> Age: 18 Years and older (Adult, Older Adult) Sex: All	Study Sponsors: Same as current Collaborators: City of Hope Medical Center	Study Start: June 13, 2022 Primary Completion: July 13, 2025 (Final data collection date for primary outcome measure) Study Completion: June 13, 2026 First Posted: May 11, 2022 Results First Posted: Last Update Posted: September 13, 2022

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
23	NCT03630211	Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis Study Documents:	Title Acronym: Other Ids: PRO18050360	Recruiting	<ul style="list-style-type: none">• Systemic Sclerosis• Diffuse Sclerosis Systemic• Interstitial Lung Disease• Pulmonary Hypertension	<ul style="list-style-type: none">• Drug: Cyclophosphamide Stem Cell Mobilization• Drug: Mesna Stem Cell Mobilization• Drug: Rituximab Transplantation Conditioning Other Name: Rituxan• Drug: Alemtuzumab Transplantation Conditioning Other Name: Campath-1H• Drug: Thiotepa Transplantation Conditioning• Drug: GM-CSF Transplantation Conditioning Other Name: Neupogen, Filgrastim• Drug: Intravenous immunoglobulin Transplantation Conditioning• Radiation: Total Body Irradiation Transplantation Conditioning• Drug: Anti Thymocyte Globulin Transplantation Conditioning Other Name: Thymoglobulin	<div>Study Type: Interventional</div> <div>Phase: Phase 2</div> <div>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</div> <div>Primary Outcome Measures:<ul style="list-style-type: none">• High Dose Immunoablative therapy-Safety [Time Frame: Up to 36 months post HSCT] Safety will be determined by monitoring for death of any cause, regimen-related toxicities, and severe or life-threatening infections.• Death [Time Frame: Post Transplant through study completion, an average of 36 months] How many, if any, patients die• Respiratory Failure [Time Frame: Post Transplant through study completion, an average of 36 months] defined by one of the following 3 criteria without explanation for causation other than disease progression: 1. decline in DLCO of 30% or FVC20% as measured by actual difference in percent predicted units; 2. Resting arterial pO2 < 60 mmHg or pCO2 > 50 mmHg supplemental oxygen;3. Resting pulse oximetry of 88% or lower measured by forehead probe.• Renal Failure [Time Frame: Post Transplant through study completion, an average of 36 months] Defined by chronic dialysis for >6 months or renal transplantation• The occurrence of cardiomyopathy [Time Frame: Post Transplant through study completion, an average of 36 months] confirmed by clinical congestive heart failure (New York Heart Association) or LVEF <30% on echocardiogram• Treatment-related mortality (TRM) [Time Frame: Mobilization through study completion, an average of 36 months] defined as death occurring at any time after stem cell mobilization and definitely or probably resulting from treatment given in the study. TRM will be determined yearly with a focus on the first 2 years.• High Dose Immunoablative therapy-Treatment Effect [Time Frame: up to 36 months post HSCT] Treatment effect will be determined by assessing event-free survival in comparison to a SSc observational cohort control group treated with standard of care medication (mycophenolate mofetil) at 12 and 36 months post hematopoietic stem cell transplant (HSCT).</div> <div>Secondary Outcome Measures:<ul style="list-style-type: none">• An increase of mRSS by 5 points for skin score [Time Frame: Disease response will be defined as subject improvement. This will be assessed for both skin and interstitial lung disease at 12 and 24 months post-HSCT.] To assess cutaneous response the modified Rodnan skin score (mRSS) will be used.• Increase by 25% if the baseline mRSS > 20. [Time Frame: Disease response will be defined as subject improvement. This will be assessed for both skin and interstitial lung disease at 12 and 24 months post-HSCT.] To assess cutaneous response the modified Rodnan skin</div>	<div>Actual Enrollment:</div> <div>Estimated Enrollment: 8</div> <div>Original Estimated Enrollment: <i>Same as current</i></div> <div>Age: 8 Years to 60 Years (Child, Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: <i>Same as current</i></div> <div>Collaborators: Not Provided</div>	<div>Study Start: July 31, 2018</div> <div>Primary Completion: August 1, 2023 (Final data collection date for primary outcome measure)</div> <div>Study Completion: August 1, 2025</div> <div>First Posted: August 14, 2018</div> <div>Results First Posted:</div> <div>Last Update Posted: September 13, 2022</div>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
24	NCT04262843	Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia Study Documents:	Title Acronym: Other Ids: 19518 NCI-2019-08984 (Registry Identifier: CTRP (Clinical Trial Reporting Program)) 19518 (Other Identifier: City of Hope Comprehensive Cancer Center)	Recruiting	<ul style="list-style-type: none">Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic Syndrome	<ul style="list-style-type: none">Drug: Cyclophosphamide Given IV Other Names:<ul style="list-style-type: none">(-)-Cyclophosphamide2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrateCarloxanCiclofosfamidaCiclofosfamideCicloxalClafenClapheneCP monohydrateCTXCYCLO-cellCycloblastinCycloblastineCyclophosphamCyclophosphamid monohydrateCyclophosphamide MonohydrateCyclophosphamidumCyclophosphanCyclophosphaneCyclophosphanumCyclostinCyclostineCytophosphanCytophosphaneCytosanFosfaseronGenoxalGenuxalLedoxinaMitoxanNeosarRevimmuneSyklofosfamidWR- 138719Drug: Fludarabine Given IV Other Name: FluradosaDrug: Fludarabine Phosphate Given IV Other Names:<ul style="list-style-type: none">2-F-ara-AMP9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-BeneflurFludaraSH T 586Biological: Granulocyte Colony-Stimulating Factor Growth factor therapy Other Names:<ul style="list-style-type: none">Colony Stimulating Factor 3Colony-Stimulating Factor (Granulocyte)Colony-Stimulating Factor 3CSF3G CSFG-CSFGranulocyte Colony Stimulating FactorPluripoietinProcedure: Hematopoietic Cell Transplantation Undergo hematopoietic cell transplantation Other Names:<ul style="list-style-type: none">HCTHematopoietic Stem Cell TransplantationHSCT	<div>Study Type: Interventional</div> <div>Phase: Phase 2</div> <div>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</div> <div>Primary Outcome Measures: <i>Same as current</i></div> <div>Secondary Outcome Measures: <i>Same as current</i></div>	<div>Actual Enrollment:</div> <div>Estimated Enrollment: 70</div> <div>Original Estimated Enrollment: <i>Same as current</i></div> <div>Age: 12 Years to 60 Years (Child, Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: <i>Same as current</i></div> <div>Collaborators: National Cancer Institute (NCI)</div>	<div>Study Start: February 7, 2020</div> <div>Primary Completion: February 4, 2024 (Final data collection date for primary outcome measure)</div> <div>Study Completion: February 4, 2024</div> <div>First Posted: February 10, 2020</div> <div>Results First Posted:</div> <div>Last Update Posted: September 16, 2022</div>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
25	NCT03190941	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Study Documents:	Title Acronym: Other Ids: 170113 17-C-0113	Recruiting	<ul style="list-style-type: none">• Pancreatic Cancer• Gastric Cancer• Gastrointestinal Cancer• Colon Cancer• Rectal Cancer	<ul style="list-style-type: none">• Drug: Cyclophosphamide Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.• Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.• Biological: Anti-KRAS G12V mTCR PBL Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).• Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).	<p>Study Type: Interventional</p> <hr/> <p>Phase: Phase 1 Phase 2</p> <hr/> <p>Study Design: Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment</p> <hr/> <p>Primary Outcome Measures:</p> <ul style="list-style-type: none">• Response rate [Time Frame: 6 weeks (+/- 2 weeks) after cell infusion, then at week 12, every 3 months x3, every 6 months x2 years.]• Maximum Tolerated Dose [Time Frame: End of treatment] <hr/> <p>Secondary Outcome Measures: Survival and persistence of mTCR gene-engineered cells. [Time Frame: approximately 4-5 years]</p>	<p>Actual Enrollment:</p> <hr/> <p>Estimated Enrollment: 110</p> <hr/> <p>Original Estimated Enrollment: <i>Same as current</i></p> <hr/> <p>Age: 18 Years to 70 Years (Adult, Older Adult)</p> <hr/> <p>Sex: All</p>	<p>Study Sponsors: Same as current</p> <hr/> <p>Collaborators: Not Provided</p>	<p>Study Start: September 21, 2017</p> <hr/> <p>Primary Completion: June 29, 2027 (Final data collection date for primary outcome measure)</p> <hr/> <p>Study Completion: June 29, 2028</p> <hr/> <p>First Posted: June 19, 2017</p> <hr/> <p>Results First Posted:</p> <hr/> <p>Last Update Posted: September 14, 2022</p>
26	NCT02830724	Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Study Documents:	Title Acronym: Other Ids: 160131 16-C-0131	Recruiting	<ul style="list-style-type: none">• Pancreatic Cancer• Renal Cell Cancer• Breast Cancer• Melanoma• Ovarian Cancer	<ul style="list-style-type: none">• Drug: Cyclophosphamide For Phase I, Days -7 and -6: Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV For Phase II, Days -7 and -6: 60 mg/kg/day x 2 days IV• Drug: Fludarabine For Phase I, Days -7 to -5: Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB For Phase II, Days -7 to -3: 25 mg/m(2)/day x 5 days IVPB• Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).• Biological: Anti-hCD70 CAR transduced PBL Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).	<p>Study Type: Interventional</p> <hr/> <p>Phase: Phase 1 Phase 2</p> <hr/> <p>Study Design: Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment</p> <hr/> <p>Primary Outcome Measures: To determine the safety of administering PBL transduced with this anti-CD70 CAR in concert with preparative lymphodepletion and high dose interleukin-2 (IL-2; aldesleukin) and to mediate regression. [Time Frame: Approximately 5 years]</p> <hr/> <p>Secondary Outcome Measures:</p> <ul style="list-style-type: none">• Determine the in vivo survival of anti-hCD70 CAR transduced cells [Time Frame: Approximately 5 years]• Determine the toxicity of this treatment regimen [Time Frame: Approximately 5 years]	<p>Actual Enrollment:</p> <hr/> <p>Estimated Enrollment: 124</p> <hr/> <p>Original Estimated Enrollment: 113</p> <hr/> <p>Age: 18 Years to 70 Years (Adult, Older Adult)</p> <hr/> <p>Sex: All</p>	<p>Study Sponsors: Same as current</p> <hr/> <p>Collaborators: Not Provided</p>	<p>Study Start: April 6, 2017</p> <hr/> <p>Primary Completion: January 1, 2027 (Final data collection date for primary outcome measure)</p> <hr/> <p>Study Completion: January 1, 2028</p> <hr/> <p>First Posted: July 13, 2016</p> <hr/> <p>Results First Posted:</p> <hr/> <p>Last Update Posted: September 15, 2022</p>

	NCT Number	Title	Other Names	Status	Conditions	Interventions	Characteristics	Population	Sponsor/Collaborators	Dates
27	NCT03548207	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma Study Documents:	<div>Title Acronym:</div> <div>Other Ids: CR108480 2018-000121-32 (EudraCT Number) 68284528MMY 2001 (Other Identifier: Janssen Research & Development, LLC)</div>	Completed	Multiple Myeloma	Biological: JNJ-68284528 JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).	<div>Study Type: Interventional</div> <div>Phase: Phase 1 Phase 2</div> <div>Study Design: Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment</div> <div>Primary Outcome Measures:<ul style="list-style-type: none">Phase 1b: Number of Participants with Adverse Events [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.Phase 1b: Number of Participants with Adverse Events by Severity [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), with the exception of cytokine release syndrome (CRS), which will be graded according to the CRS revised grading system (Grade 1 to Grade 5) where Grade 1 being mild, asymptomatic or mild symptoms and Grade 5 indicating death related to adverse event.Phase 2: Overall Response Rate (ORR) [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] The ORR is defined as the proportion of participants who achieve partial response (PR) or better according to international myeloma working group (IMWG) criteria.</div> <div>Secondary Outcome Measures:<ul style="list-style-type: none">Phase 2: Number of Participants with Adverse Events [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.Chimeric Antigen Receptor T (cells) (CAR-T) Positive Cellular Concentration of JNJ-68284528 [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] Post-dose blood and bone marrow samples will be analyzed to determine CAR-T positive cellular concentration.Transgene Levels of JNJ-68284528 [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] Transgene levels of JNJ-68284528 using specific and sensitive assay methods will be assessed.Levels of B-Cell Maturation Antigen (BCMA) Expressing Cells and Soluble BCMA [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] Levels of expression of BCMA-expressing plasma cells in the bone marrow as well as the level of soluble BCMA in blood will be reported.Systemic Cytokine Concentrations [Time Frame: Minimum 2 years after JNJ-68284528 infusion (Day 1)] Serum cytokine concentrations (Interleukin [IL]-6, IL-15, IL-10, and Interferon [IFN-g]) will be measured for biomarker assessment.</div>	<div>Actual Enrollment: 126</div> <div>Estimated Enrollment:</div> <div>Original Estimated Enrollment: 84</div> <div>Age: 18 Years and older (Adult, Older Adult)</div> <div>Sex: All</div>	<div>Study Sponsors: Same as current</div> <div>Collaborators: Not Provided</div>	<div>Study Start: June 29, 2018</div> <div>Primary Completion: August 23, 2022 (Final data collection date for primary outcome measure)</div> <div>Study Completion: August 23, 2022</div> <div>First Posted: June 7, 2018</div> <div>Results First Posted:</div> <div>Last Update Posted: September 16, 2022</div>